ast week, Leerink Partners healthcare analysts Geoffrey Porges, Seamus Fernandez, and Paul Matteis dropped by the STAT offices for a conversation with biotech reporters Damian Garde and Adam Feuerstein.

In this edited excerpt, the Leerink analysts discuss the evolving role of the sell-side analyst on Wall Street. Price targets and stock ratings — though widely ridiculed — still matter, they say. And they have answers to the critics who accuse sell-siders of being feckless sycophants willing to do or say anything to stay in the good graces of investment-banking clients.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy